- Home
- CXM vs MIRM Comparison
CXM vs MIRM Comparison
Compare CXM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXM
- MIRM
- Stock Information
- Founded
- CXM 2009
- MIRM 2018
- Country
- CXM United States
- MIRM United States
- Employees
- CXM N/A
- MIRM N/A
- Industry
- CXM Computer Software: Prepackaged Software
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- CXM Technology
- MIRM Health Care
- Exchange
- CXM Nasdaq
- MIRM Nasdaq
- Market Cap
- CXM 2.3B
- MIRM 1.9B
- IPO Year
- CXM 2021
- MIRM 2019
- Fundamental
- Price
- CXM $9.37
- MIRM $41.88
- Analyst Decision
- CXM Hold
- MIRM Strong Buy
- Analyst Count
- CXM 15
- MIRM 12
- Target Price
- CXM $9.89
- MIRM $57.58
- AVG Volume (30 Days)
- CXM 3.0M
- MIRM 356.2K
- Earning Date
- CXM 12-04-2024
- MIRM 11-12-2024
- Dividend Yield
- CXM N/A
- MIRM N/A
- EPS Growth
- CXM 36.57
- MIRM N/A
- EPS
- CXM 0.15
- MIRM N/A
- Revenue
- CXM $788,062,000.00
- MIRM $307,028,000.00
- Revenue This Year
- CXM $8.44
- MIRM $82.14
- Revenue Next Year
- CXM $4.31
- MIRM $26.18
- P/E Ratio
- CXM $61.43
- MIRM N/A
- Revenue Growth
- CXM 12.02
- MIRM 112.14
- 52 Week Low
- CXM $6.91
- MIRM $23.14
- 52 Week High
- CXM $14.32
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- CXM 68.88
- MIRM 42.64
- Support Level
- CXM $8.81
- MIRM $41.58
- Resistance Level
- CXM $9.47
- MIRM $43.37
- Average True Range (ATR)
- CXM 0.36
- MIRM 1.67
- MACD
- CXM 0.05
- MIRM -0.48
- Stochastic Oscillator
- CXM 95.24
- MIRM 7.05
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in providing enterprise software that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, and communicate across digital channels. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in Americas, EMEA and other countries. It derives maximum revenue from Americas.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.